Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 5/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264592 | 1.00 | PNMT (0.46) | PNMTSCN9ACES2TACR1IDO1 | |
| SCHEMBL6484095 | 1.00 | PNMT (0.46) | PNMTSCN9ACES2TACR1IDO1 | |
| SCHEMBL29256555 | 0.88 | PNMT (0.41) | PNMTSCN9ACES2PDE2AGRIN2B | |
| SCHEMBL30988810 | 0.88 | PNMT (0.41) | PNMTSCN9ACES2PDE2AGRIN2B | |
| SCHEMBL29256557 | 0.88 | PNMT (0.41) | PNMTSCN9ACES2PDE2AGRIN2B | |
| SCHEMBL25920947 | 0.84 | PNMT (0.47) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL2394599 | 0.81 | PDE2A (0.51) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL7787286 | 0.81 | PNMT (0.49) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL5610427 | 0.81 | PDE2A (0.51) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL531699 | 0.81 | PNMT (0.68) | PNMTCES2TACR1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340754-B | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250065315-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4491270-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | The University of Hong Kong (HK) | 2025-01-15 | — | — | EP | disclosed |
| CN-119306769-A | Iron complexes for enantioselective cis dihydroxylation of olefins | 香港大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-118340754-A | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2024-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250065315-A1 | IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES | SQLE, NFE2L2, FECH | PNMT 1065/4885SCN9A 3683/4885CES2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.